Latvija - latviešu - Zāļu valsts aģentūra

g.l. pharma gmbh, austria - aripiprazols - tablete - 15 mg

Latvija - latviešu - Zāļu valsts aģentūra

g.l. pharma gmbh, austria - aripiprazols - tablete - 10 mg

Latvija - latviešu - Zāļu valsts aģentūra

aspen pharma trading ltd., ireland - bupivakaīna hidrohlorīds - Šķīdums injekcijām - 5 mg/ml

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

intervet ireland ltd, Īrija - dzīvot Ņūkāslas slimības vīrusu - liofilizāts okulonazālas suspensijas pagatavošanai - vistas

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

intervet ireland ltd, Īrija - dzīvot gumboro slimības vīruss - liofilizāts okulonazālas suspensijas pagatavošanai/lietošanai dzeramajā ūdenī - vistas

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

intervet ireland ltd, Īrija - live attenuated avian rhinotracheitis virus - liofilizāts suspensijas pagatavošanai okulonazālai aplikācijai vai izsmidzināšanai - vistas

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - imipenem monohidrāts, cilastatin nātrija, relebactam monohidrāts - gram-negatīvo baktēriju infekcijas - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 un 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4. un 5.. jāņem vērā oficiālās vadlīnijas par piemērotu izmantot antibakteriālas vielas.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imūnsupresanti - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Latvija - latviešu - Adama

adama - suspensijas koncentrāts - diflufenikans + hlorotolurons + pendametalīns - herbicīdi